Latest news with #Bexotegrast
Yahoo
21-05-2025
- Business
- Yahoo
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025. Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS from Multiple ILD SubtypesIn a featured oral presentation, Johanna Schaub, Ph.D., Director of Translational Sciences at Pliant Therapeutics, discussed an evaluation of the antifibrotic activity of bexotegrast in fibrotic human precision-cut lung slices (PCLS) generated from non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) patient lung explants. Results showed that bexotegrast, a dual inhibitor of αVβ6/αVβ1 integrins, reduced expression of genes related to TGF-β signaling and fibrogenesis in alveolar type 1 (AT1) cells and multiple fibroblast subpopulations. Plasma Proteome Analysis Reveals Shared and Unique Biomarkers of ILD SubtypesIn a poster presentation, Erine Budi, Ph.D., Senior Scientist II Translational Biology at Pliant Therapeutics, reviewed a comparative analysis assessing circulating plasma biomarkers of ILD in healthy subjects and patients with idiopathic pulmonary fibrosis (IPF), rheumatoid arthritis-ILD (RA-ILD), and scleroderma associated-ILD (SSc-ILD). Results identified biomarkers consistently dysregulated across multiple ILD subtypes that could assist in informing clinical decision making in ILD. Single-Cell Profiling Demonstrates the Antifibrotic Effects of Bexotegrast on Pathologic Lung Cell Populations in the Presence and Absence of Background TherapyIn a poster presentation, Mahru An, Ph.D., Director of Translational Sciences at Pliant Therapeutics, reviewed a single-nuclei RNAseq analysis of fibrotic human precision-cut lung slices comparing the pharmacodynamic effects of bexotegrast, a dual inhibitor of αVβ6 and αVβ1 integrins, alone, or in combination with nintedanib. Results showed that treatment with bexotegrast or nintedanib displayed distinct cell-specific pharmacodynamic profiles. In addition, bexotegrast alone, or in the presence of nintedanib, significantly reduced the expression of type I collagen and other profibrotic genes in aberrant basaloid cells (αVβ6-expressing) and fibroblasts (αVβ1-expressing), while treatment with nintedanib alone did not. The presentation and posters presented at the 2025 ATS Conference are available by accessing the links above or on Pliant's website under the Publications section at About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is undergoing evaluation for the treatment of idiopathic pulmonary fibrosis, or IPF. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation from the European Medicines Agency in IPF. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies. For additional information, please visit: Follow us on social media X, LinkedIn, and Facebook. Investor and Media Contact: Christopher KeenanVice President, Investor Relations and Corporate CommunicationsPliant Therapeutics,
Yahoo
21-05-2025
- Business
- Yahoo
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025. Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS from Multiple ILD SubtypesIn a featured oral presentation, Johanna Schaub, Ph.D., Director of Translational Sciences at Pliant Therapeutics, discussed an evaluation of the antifibrotic activity of bexotegrast in fibrotic human precision-cut lung slices (PCLS) generated from non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) patient lung explants. Results showed that bexotegrast, a dual inhibitor of αVβ6/αVβ1 integrins, reduced expression of genes related to TGF-β signaling and fibrogenesis in alveolar type 1 (AT1) cells and multiple fibroblast subpopulations. Plasma Proteome Analysis Reveals Shared and Unique Biomarkers of ILD SubtypesIn a poster presentation, Erine Budi, Ph.D., Senior Scientist II Translational Biology at Pliant Therapeutics, reviewed a comparative analysis assessing circulating plasma biomarkers of ILD in healthy subjects and patients with idiopathic pulmonary fibrosis (IPF), rheumatoid arthritis-ILD (RA-ILD), and scleroderma associated-ILD (SSc-ILD). Results identified biomarkers consistently dysregulated across multiple ILD subtypes that could assist in informing clinical decision making in ILD. Single-Cell Profiling Demonstrates the Antifibrotic Effects of Bexotegrast on Pathologic Lung Cell Populations in the Presence and Absence of Background TherapyIn a poster presentation, Mahru An, Ph.D., Director of Translational Sciences at Pliant Therapeutics, reviewed a single-nuclei RNAseq analysis of fibrotic human precision-cut lung slices comparing the pharmacodynamic effects of bexotegrast, a dual inhibitor of αVβ6 and αVβ1 integrins, alone, or in combination with nintedanib. Results showed that treatment with bexotegrast or nintedanib displayed distinct cell-specific pharmacodynamic profiles. In addition, bexotegrast alone, or in the presence of nintedanib, significantly reduced the expression of type I collagen and other profibrotic genes in aberrant basaloid cells (αVβ6-expressing) and fibroblasts (αVβ1-expressing), while treatment with nintedanib alone did not. The presentation and posters presented at the 2025 ATS Conference are available by accessing the links above or on Pliant's website under the Publications section at About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is undergoing evaluation for the treatment of idiopathic pulmonary fibrosis, or IPF. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation from the European Medicines Agency in IPF. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies. For additional information, please visit: Follow us on social media X, LinkedIn, and Facebook. Investor and Media Contact: Christopher KeenanVice President, Investor Relations and Corporate CommunicationsPliant Therapeutics, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-05-2025
- Business
- Yahoo
Pliant cuts workforce by 45% following lung trial termination
Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the biotech disclosed after market close on 1 May. The move comes just weeks after the company halted its late-stage BEACON-IPF Phase IIb/III trial (NCT06097260) of bexotegrast, its lead drug candidate for idiopathic pulmonary fibrosis (IPF), following safety concerns. The layoffs are expected to affect all departments and are part of a broader cost-saving strategy designed to preserve capital ahead of critical topline data from the now-discontinued trial. While the company has not seen the final dataset, it anticipates receiving the data in the second quarter of 2025 (Q2 2025). Once available, Pliant plans to assess potential next steps for bexotegrast's development, which could include additional dose-ranging studies in pulmonary fibrosis or new indications such as liver diseases. The BEACON-IPF study was halted in March 2025 after an independent data monitoring board and external expert panel identified an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo arms. Although the company reported signs of efficacy – specifically early improvements in forced vital capacity – it opted to suspend the trial out of caution. Pliant said the restructuring is intended to ensure it can continue executing on its remaining clinical programmes without interruption. Bexotegrast, an oral, small-molecule, dual-selective inhibitor of the αvβ6 and αvβ1 integrins, is also being studied for primary sclerosing cholangitis. In addition to this, Pliant is advancing candidate PLN-101095 for solid tumours and PLN-101325 for muscular dystrophies. The restructuring is set for substantial completion by the end of Q2 2025, ahead of Pliant's Q1 2025 financial results and corporate update on 8 May 2025. The IPF treatment space remains competitive, with few US Food and Drug Administration-approved therapies. Boehringer Ingelheim's Ofev (nintedanib) and Roche's Esbriet (pirfenidone) dominate the market, although Esbriet's revenues have declined significantly in the past few years with the entry of generics. The drug earned SFr202m ($245m) in sales in 2023, dropping to SFr94m in 2024, as per Roche's financials. Meanwhile, Boehringer is advancing nerandomilast, which recently met its primary endpoint in the Phase III FIBRONEER-IPF trial (NCT05321069) for IPF. The company has submitted a new drug application. "Pliant cuts workforce by 45% following lung trial termination " was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
10-02-2025
- Business
- Yahoo
Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive
Pliant Therapeutics (PLRX, Financials) shares tumbled 58.8% to $3.21 as of 12:40 p.m. ET on Monday, following a 34.8% decline on Friday, after the company announced a voluntary pause in enrollment and dosing for its BEACON-IPF Phase 2b trial. Warning! GuruFocus has detected 3 Warning Signs with PLRX. The independent Data Safety Monitoring Board of the trial is cited as the reason for the choice. The suspension, according to the business, will provide time for data assessment and DSMB justification understanding. The study will remain blinded in order to maintain its integrity; patients already enrolled in it will stay in the experiment. Pliant is now alerting worldwide regulatory authorities and has alerted clinical trial investigators. Targeting ?v?6 and ?v?1 integrins, proteins linked in fibrosis, Bexotegrast is an oral small-molecule inhibitor being studied. The U.S. Food and Drug Administration has assigned it Fast Track and Orphan Drug designations; the European Medicines Agency has assigned it Orphan Drug status. The BEACON-IPF study is assessing the medication as a possible therapy for the progressive lung illness known as idiopathic pulmonary fibrosis, for which there are few therapeutic choices. Pliant said it is still dedicated to working with authorities and the DSMB to decide the best course ahead, but it did not provide a restarting enrollment timetable. As additional data becomes available, the business said it would provide updates. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
10-02-2025
- Business
- Yahoo
Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive
Pliant Therapeutics (PLRX, Financials) shares tumbled 58.8% to $3.21 as of 12:40 p.m. ET on Monday, following a 34.8% decline on Friday, after the company announced a voluntary pause in enrollment and dosing for its BEACON-IPF Phase 2b trial. Warning! GuruFocus has detected 3 Warning Signs with PLRX. The independent Data Safety Monitoring Board of the trial is cited as the reason for the choice. The suspension, according to the business, will provide time for data assessment and DSMB justification understanding. The study will remain blinded in order to maintain its integrity; patients already enrolled in it will stay in the experiment. Pliant is now alerting worldwide regulatory authorities and has alerted clinical trial investigators. Targeting ?v?6 and ?v?1 integrins, proteins linked in fibrosis, Bexotegrast is an oral small-molecule inhibitor being studied. The U.S. Food and Drug Administration has assigned it Fast Track and Orphan Drug designations; the European Medicines Agency has assigned it Orphan Drug status. The BEACON-IPF study is assessing the medication as a possible therapy for the progressive lung illness known as idiopathic pulmonary fibrosis, for which there are few therapeutic choices. Pliant said it is still dedicated to working with authorities and the DSMB to decide the best course ahead, but it did not provide a restarting enrollment timetable. As additional data becomes available, the business said it would provide updates. This article first appeared on GuruFocus.
